With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.53617-36-0,1-Methyl-4-(piperidin-4-yl)piperazine,as a common compound, the synthetic route is as follows.
7g) (R)-1-(8-methyl-imidazo[1.5-a]pyridin-6-ylmethyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate A solution of 115 mg (0.18 mmol) (R)-1-carboxy-2-(8-methyl-imidazo[1,5-a]pyridin-6-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate, 70 mg (0.22 mmol) TBTU and 40 muL (0.29 mmol) triethylamine in 10 mL THF and 1 mL DMF was stirred for 1 h at RT. Then 50 mg (0.27 mmol) 1-methyl-4-piperidin-4-yl-piperazine were added and the reaction mixture was stirred overnight at RT. To complete the reaction another 70 mg TBTU and 50 mg 1-methyl-4-piperidin-4-yl-piperazine were added, the mixture was stirred for a further 65 h at RT and again combined with 70 mg TBTU, 50 mg 1-methyl-4-piperidin-4-yl-piperazine, 40 muL triethylamine and 1 mL DMF and stirred overnight at RT. 10 mL semisaturated NaHCO3 solution were added to the reaction mixture, it was extracted twice with 30 mL EtOAc and the combined organic phases were dried over Na2SO4. After the desiccant and solvent had been eliminated the residue was purified by HPLC. The fractions containing the product were combined and lyophilised. Yield: 49 mg (29percent of theory) ESI-MS: (M+H)+=657 retention time (HPLC): 2.0 min (method B), 53617-36-0
As the paragraph descriping shows that 53617-36-0 is playing an increasingly important role.
Reference：
Patent; Boehringer Ingelheim International GmbH; US2005/256099; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem